ArticleProstate cancer and prostatic diseases2025

Abiraterone for "STAMPEDE-Like" cohort of high-risk prostate cancer in the PSMA-PET era: too much, too early?

Vedang Murthy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.